Form 8-K · Current Report · Filed 2025-10-30
Gilead Sciences Reports Q3 2025 Financial Results and Business Updates
Gilead Sciences, Inc. reported its third quarter 2025 financial results, showing a total revenue of $7.8 billion, a 3% increase year-over-year. Product sales excluding Veklury increased by 4% to $7.1 billion, driven by higher sales of HIV and liver disease products. Diluted earnings per share (EPS) were $2.43, significantly higher than the $1.00 reported in Q3 2024. Gilead also provided an update on its product pipeline and recent patent settlement agreements for Biktarvy.
- Filer
- Gilead Sciences Inc. GILD · NASDAQ
- Filed
- Accession
- 0000882095-25-000044
- CIK
- 0000882095
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Market reaction
Close before filing
$118.50
Next session
+1.1%
Since filing
+9.9%
Latest close
$130.21
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from GILD reporting the same item, with the next session's move:
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Never miss another GILD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.